BioCryst Pharmaceuticals vs Moderna
BCRX and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and MRNA compare
Moderna is the larger company, worth 41 times as much as BioCryst Pharmaceuticals ($88.5B against $2.2B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus −27.6% for Moderna).
BioCryst Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −40.9% compared with −141% at Moderna.
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $88.5B |
| Share price | $8.47 | $221.72 |
| Change, 1 year | 15.9% | 798% |
| Change, 5 years | −31.7% | −6.4% |
| Beta (5Y) | 0.80 | 1.11 |
| Employees | 435 | 4,700 |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 39.7× |
| P/B | – | 13.1× |
| P/FCF | 5.8× | – |
| FCF yield | 17.3% (better) | −1.4% |
| Fair value | – | $33.24 |
| Margin of safety | – | −567% |
| Growth | ||
| Revenue growth (TTM) | 68.7% (better) | −27.6% |
| Revenue growth, 5Y average | 118% (better) | 19.3% |
| Profitability | ||
| Gross margin | 97.8% (better) | 23.4% |
| Operating margin | −33.3% (better) | −149% |
| Net margin | −40.9% (better) | −141% |
| FCF margin | 39.7% (better) | −55.8% |
| Return on equity | – | −39.0% |
| Return on invested capital | – | −80.9% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Interest coverage | −4.2× | – |
| Current ratio | 2.32 (better) | 2.29 |
| Altman Z-score | −3.68 | 12.86 (better) |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 79.9% |
| Held by insiders | 1.9% | 5.6% |
| Insider net buying, 12 months | −$4.1M (better) | −$64.6M |
| Short interest, % of float | 11.0% | 8.2% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.